Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma

Published:2023-10 Issue: Volume:166 Page:115351
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Sun Tao,Sun Bo,Cao Yanyan,Liu Jiayun,Chen Juan,Liang Bin,Zheng Chuansheng,Kan Xuefeng^ORCID

Publisher

Elsevier BV

Reference48 articles.

1. Is there a role for percutaneous ablation for early stage lung cancer? What is the evidence?;Palussière;Curr. Oncol. Rep.,2021

2. Safety and efficacy of RFA versus MWA for T1a renal cell carcinoma: a propensity score analysis;Aarts;Eur. Radiol.,2022

3. Quality improvement guidelines for radiofrequency ablation of liver tumours;Crocetti;Cardiovasc. Interv. Radiol.,2010

4. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas;Kim;Br. J. Surg.,2016

5. Results of liver resection in combination with radiofrequency ablation for hepatic malignancies;Eisele;Eur. J. Surg. Oncol.,2010

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blocking Tim-3 enhances CD8 ⁺ T cell activity to inhibit hepatocellular carcinoma recurrence post-radiofrequency ablation;International Journal of Hyperthermia;2025-06-16

2. Anti-PD-1 synergizes with RFA to suppress abscopal tumors and induce durable memory against recurrence in HCC;Liver Research;2025-06

3. Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma;Cell Death & Disease;2025-04-13

4. Radiofrequency ablation: mechanisms and clinical applications;MedComm;2024-10

5. oHSV2-mGM repolarizes TAMs and cooperates with αPD1 to reprogram the immune microenvironment of residual cancer after radiofrequency ablation;Biomedicine & Pharmacotherapy;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.7亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3